Model-Based Dosing of Anti-Thymocyte Globulin in Pediatric Allogeneic Hematopoietic Cell Transplantation Improves Survival Chances: Updated Results from the Single Arm Phase II Parachute-Trial Combined with Real-World Data
Rick Admiraal(NHS Blood and Transplant), Caroline A. Lindemans(University Medical Center Utrecht), Yilin Jiang(Princess Máxima Center), C. Michel Zwaan(Hôpital Saint-Michel), Andrew C. Harris(Primary Children's Hospital), Robbert G. M. Bredius(Leiden University Medical Center), Friso Calkoen(Princess Máxima Center), Elizabeth Klein(Memorial Sloan Kettering Cancer Center), Maria Cancio(Memorial Sloan Kettering Cancer Center), Kevin J. Curran(Memorial Sloan Kettering Cancer Center), Dorine Bresters(Willem-Alexander Kinderziekenhuis), Wouter J.W. Kollen(Princess Máxima Center), Marc Bierings(University Medical Center Utrecht), A. Birgitta Versluijs(NHS Blood and Transplant), Andromachi Scaradavou(NewYork–Presbyterian Hospital), Stefan Nierkens(Utrecht University), Jaap Jan Boelens(Wilhelmina Children's Hospital), Mirjam E. Belderbos(Princess Máxima Center), Alwin D. R. Huitema(The Netherlands Cancer Institute)
Cited by 2
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k